{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:36:32Z","timestamp":1787240192029,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12035-024-04612-8","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:30:00Z","timestamp":1732069800000},"page":"5518-5530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetic Insights into Therapeutic Targets for Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study"],"prefix":"10.1007","volume":"62","author":[{"given":"Yangyue","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"issue":"1","key":"4612_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","volume":"18","author":"RA Kessler","year":"2016","unstructured":"Kessler RA, Mealy MA, Levy M (2016) Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol 18(1):2. https:\/\/doi.org\/10.1007\/s11940-015-0387-9","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"4612_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","volume":"176","author":"S Jarius","year":"2014","unstructured":"Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176(2):149\u2013164. https:\/\/doi.org\/10.1111\/cei.12271","journal-title":"Clin Exp Immunol"},{"key":"4612_CR3","doi-asserted-by":"publisher","first-page":"174720","DOI":"10.1155\/2015\/174720","volume":"2015","author":"M Etemadifar","year":"2015","unstructured":"Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R (2015) Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult Scler Int 2015:174720. https:\/\/doi.org\/10.1155\/2015\/174720","journal-title":"Mult Scler Int"},{"issue":"1","key":"4612_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/wno.0000000000000102","volume":"34","author":"MC Kowarik","year":"2014","unstructured":"Kowarik MC, Soltys J, Bennett JL (2014) The treatment of neuromyelitis optica. J Neuroophthalmol 34(1):70\u201382. https:\/\/doi.org\/10.1097\/wno.0000000000000102","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"4612_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","volume":"13","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gold R (2016) Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 13(1):70\u201383. https:\/\/doi.org\/10.1007\/s13311-015-0400-8","journal-title":"Neurotherapeutics"},{"issue":"4","key":"4612_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","volume":"92","author":"BG Weinshenker","year":"2017","unstructured":"Weinshenker BG, Wingerchuk DM (2017) Neuromyelitis spectrum disorders. Mayo Clin Proc 92(4):663\u2013679. https:\/\/doi.org\/10.1016\/j.mayocp.2016.12.014","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"4612_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P (2015) The support of human genetic evidence for approved drug indications. Nat Genet 47(8):856\u2013860. https:\/\/doi.org\/10.1038\/ng.3314","journal-title":"Nat Genet"},{"issue":"1","key":"4612_CR8","doi-asserted-by":"publisher","first-page":"18911","DOI":"10.1038\/s41598-019-54849-w","volume":"9","author":"AD Hingorani","year":"2019","unstructured":"Hingorani AD, Kuan V, Finan C, Kruger FA, Gaulton A, Chopade S, Sofat R, MacAllister RJ, Overington JP, Hemingway H, Denaxas S, Prieto D, Casas JP (2019) Improving the odds of drug development success through human genomics: modelling study. Sci Rep 9(1):18911. https:\/\/doi.org\/10.1038\/s41598-019-54849-w","journal-title":"Sci Rep"},{"key":"4612_CR9","doi-asserted-by":"publisher","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R, et al (2017) The druggable genome and support for target identification and validation in drug development. Sci Transl Med 9 (383). https:\/\/doi.org\/10.1126\/scitranslmed.aag1166","DOI":"10.1126\/scitranslmed.aag1166"},{"issue":"1","key":"4612_CR10","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Mara\u00f1\u00f3n M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R et al (2020) Genetic drug target validation using Mendelian randomisation. Nat Commun 11(1):3255. https:\/\/doi.org\/10.1038\/s41467-020-16969-0","journal-title":"Nat Commun"},{"issue":"12","key":"4612_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/s1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA et al (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18(12):1091\u20131102. https:\/\/doi.org\/10.1016\/s1474-4422(19)30320-5","journal-title":"Lancet Neurol"},{"issue":"6","key":"4612_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mds.27659","volume":"34","author":"C Blauwendraat","year":"2019","unstructured":"Blauwendraat C, Heilbron K, Vallerga CL, Bandres-Ciga S, von Coelln R, Pihlstr\u00f8m L, Sim\u00f3n-S\u00e1nchez J, Schulte C et al (2019) Parkinson\u2019s disease age at onset genome-wide association study: defining heritability, genetic loci, and \u03b1-synuclein mechanisms. Mov Disord 34(6):866\u2013875. https:\/\/doi.org\/10.1002\/mds.27659","journal-title":"Mov Disord"},{"issue":"8479","key":"4612_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/s0140-6736(86)92972-7","volume":"1","author":"MB Katan","year":"1986","unstructured":"Katan MB (1986) Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1(8479):507\u2013508. https:\/\/doi.org\/10.1016\/s0140-6736(86)92972-7","journal-title":"Lancet"},{"issue":"10","key":"4612_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","volume":"14","author":"MV Holmes","year":"2017","unstructured":"Holmes MV, Ala-Korpela M, Smith GD (2017) Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol 14(10):577\u2013590. https:\/\/doi.org\/10.1038\/nrcardio.2017.78","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"4612_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ng.3538","volume":"48","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard ME et al (2016) Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet 48(5):481\u2013487. https:\/\/doi.org\/10.1038\/ng.3538","journal-title":"Nat Genet"},{"issue":"10","key":"4612_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/circulationaha.119.040180","volume":"140","author":"M Chong","year":"2019","unstructured":"Chong M, Sjaarda J, Pigeyre M, Mohammadi-Shemirani P, Lali R, Shoamanesh A, Gerstein HC, Par\u00e9 G (2019) Novel drug targets for ischemic stroke identified through mendelian randomization analysis of the blood proteome. Circulation 140(10):819\u2013830. https:\/\/doi.org\/10.1161\/circulationaha.119.040180","journal-title":"Circulation"},{"issue":"2","key":"4612_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41588-020-00773-z","volume":"53","author":"AP Wingo","year":"2021","unstructured":"Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, Dammer EB, Robins C et al (2021) Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer\u2019s disease pathogenesis. Nat Genet 53(2):143\u2013146. https:\/\/doi.org\/10.1038\/s41588-020-00773-z","journal-title":"Nat Genet"},{"issue":"1","key":"4612_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/brain\/awad321","volume":"147","author":"C Qin","year":"2024","unstructured":"Qin C, Chen M, Dong MH, Yang S, Zhang H, You YF, Zhou LQ, Chu YH et al (2024) Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders. Brain 147(1):163\u2013176. https:\/\/doi.org\/10.1093\/brain\/awad321","journal-title":"Brain"},{"key":"4612_CR19","doi-asserted-by":"publisher","first-page":"1418309","DOI":"10.3389\/fimmu.2024.1418309","volume":"15","author":"X Ma","year":"2024","unstructured":"Ma X, Wang Y, Chen X, Guo J (2024) The levels of circulating cytokines and risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study. Front Immunol 15:1418309. https:\/\/doi.org\/10.3389\/fimmu.2024.1418309","journal-title":"Front Immunol"},{"issue":"9","key":"4612_CR20","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","volume":"53","author":"U V\u00f5sa","year":"2021","unstructured":"V\u00f5sa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, Kirsten H, Saha A et al (2021) Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet 53(9):1300\u20131310. https:\/\/doi.org\/10.1038\/s41588-021-00913-z","journal-title":"Nat Genet"},{"issue":"2","key":"4612_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/wnl.0000000000001729","journal-title":"Neurology"},{"key":"4612_CR22","doi-asserted-by":"publisher","first-page":"1305650","DOI":"10.3389\/fimmu.2023.1305650","volume":"14","author":"S Wang","year":"2023","unstructured":"Wang S, Wang L, Wang J, Zhu M (2023) Causal relationships between susceptibility and severity of COVID-19 and neuromyelitis optica spectrum disorder (NMOSD) in European population: a bidirectional Mendelian randomized study. Front Immunol 14:1305650. https:\/\/doi.org\/10.3389\/fimmu.2023.1305650","journal-title":"Front Immunol"},{"issue":"34","key":"4612_CR23","doi-asserted-by":"publisher","first-page":"e2306153120","DOI":"10.1073\/pnas.2306153120","volume":"120","author":"A Monavarfeshani","year":"2023","unstructured":"Monavarfeshani A, Yan W, Pappas C, Odenigbo KA, He Z, Segr\u00e8 AV, van Zyl T, Hageman GS, Sanes JR (2023) Transcriptomic analysis of the ocular posterior segment completes a cell atlas of the human eye. Proc Natl Acad Sci U S A 120(34):e2306153120. https:\/\/doi.org\/10.1073\/pnas.2306153120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"4612_CR24","doi-asserted-by":"publisher","first-page":"e2200914119","DOI":"10.1073\/pnas.2200914119","volume":"119","author":"T van Zyl","year":"2022","unstructured":"van Zyl T, Yan W, McAdams AM, Monavarfeshani A, Hageman GS, Sanes JR (2022) Cell atlas of the human ocular anterior segment: tissue-specific and shared cell types. Proc Natl Acad Sci U S A 119(29):e2200914119. https:\/\/doi.org\/10.1073\/pnas.2200914119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4612_CR25","doi-asserted-by":"publisher","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic acids research 46 (D1):D1074-d1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037","DOI":"10.1093\/nar\/gkx1037"},{"key":"4612_CR26","doi-asserted-by":"publisher","first-page":"16645","DOI":"10.1038\/srep16645","volume":"5","author":"LA Millard","year":"2015","unstructured":"Millard LA, Davies NM, Timpson NJ, Tilling K, Flach PA, Davey Smith G (2015) MR-PheWAS: hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization. Sci Rep 5:16645. https:\/\/doi.org\/10.1038\/srep16645","journal-title":"Sci Rep"},{"key":"4612_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Kutalik Z et al (2019) Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome open research 4:186. https:\/\/doi.org\/10.12688\/wellcomeopenres.15555.3","journal-title":"Wellcome open research"},{"issue":"5725","key":"4612_CR28","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1126\/science.1109418","volume":"308","author":"DB Gould","year":"2005","unstructured":"Gould DB, Phalan FC, Breedveld GJ, van Mil SE, Smith RS, Schimenti JC, Aguglia U, van der Knaap MS et al (2005) Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science (New York, NY) 308(5725):1167\u20131171. https:\/\/doi.org\/10.1126\/science.1109418","journal-title":"Science (New York, NY)"},{"issue":"14","key":"4612_CR29","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa053727","volume":"354","author":"DB Gould","year":"2006","unstructured":"Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, Bousser MG, Heutink P et al (2006) Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 354(14):1489\u20131496. https:\/\/doi.org\/10.1056\/NEJMoa053727","journal-title":"N Engl J Med"},{"issue":"1","key":"4612_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/15563659109038598","volume":"29","author":"JB Leikin","year":"1991","unstructured":"Leikin JB, Goldman-Leikin RE, Evans MA, Wiener S, Hryhorczuk DO (1991) Immunotherapy in acute arsenic poisoning. J Toxicol Clin Toxicol 29(1):59\u201370. https:\/\/doi.org\/10.3109\/15563659109038598","journal-title":"J Toxicol Clin Toxicol"},{"issue":"R1","key":"4612_CR31","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1093\/hmg\/dds346","volume":"21","author":"DS Kuo","year":"2012","unstructured":"Kuo DS, Labelle-Dumais C, Gould DB (2012) COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets. Hum Mol Genet 21(R1):R97-110. https:\/\/doi.org\/10.1093\/hmg\/dds346","journal-title":"Hum Mol Genet"},{"issue":"5","key":"4612_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36(5):411\u2013420. https:\/\/doi.org\/10.1038\/nbt.4096","journal-title":"Nat Biotechnol"},{"issue":"3","key":"4612_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/ng0397-316","volume":"15","author":"AV Pshezhetsky","year":"1997","unstructured":"Pshezhetsky AV, Richard C, Michaud L, Igdoura S, Wang S, Elsliger MA, Qu J, Leclerc D et al (1997) Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet 15(3):316\u2013320. https:\/\/doi.org\/10.1038\/ng0397-316","journal-title":"Nat Genet"},{"issue":"1\u20133","key":"4612_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0014-5793(02)02748-5","volume":"521","author":"J Uhl","year":"2002","unstructured":"Uhl J, Penzel R, Sergi C, Kopitz J, Otto HF, Cantz M (2002) Identification of a CTL4\/Neu1 fusion transcript in a sialidosis patient. FEBS Lett 521(1\u20133):19\u201323. https:\/\/doi.org\/10.1016\/s0014-5793(02)02748-5","journal-title":"FEBS Lett"},{"key":"4612_CR35","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.bbadis.2013.06.002","volume":"10","author":"EJ Bonten","year":"1832","unstructured":"Bonten EJ, Yogalingam G, Hu H, Gomero E, van de Vlekkert D (1832) d\u2019Azzo A (2013) Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochem Biophys Acta 10:1784\u20131792. https:\/\/doi.org\/10.1016\/j.bbadis.2013.06.002","journal-title":"Biochem Biophys Acta"},{"key":"4612_CR36","doi-asserted-by":"publisher","first-page":"902259","DOI":"10.3389\/fphar.2022.902259","volume":"13","author":"A Khan","year":"2022","unstructured":"Khan A, Sergi CM (2022) NEU1-a unique therapeutic target for Alzheimer\u2019s disease. Front Pharmacol 13:902259. https:\/\/doi.org\/10.3389\/fphar.2022.902259","journal-title":"Front Pharmacol"},{"issue":"10","key":"4612_CR37","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1007\/s00415-023-11776-1","volume":"270","author":"R Wang","year":"2023","unstructured":"Wang R, Sun D, Du Q, Shi Z, Chen H, Zhou H (2023) Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report. J Neurol 270(10):5085\u20135089. https:\/\/doi.org\/10.1007\/s00415-023-11776-1","journal-title":"J Neurol"},{"issue":"11","key":"4612_CR38","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73(11):1342\u20131348. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1637","journal-title":"JAMA Neurol"},{"issue":"1","key":"4612_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/s1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20(1):60\u201367. https:\/\/doi.org\/10.1016\/s1474-4422(20)30392-6","journal-title":"Lancet Neurol"},{"issue":"7","key":"4612_CR40","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381(7):614\u2013625. https:\/\/doi.org\/10.1056\/NEJMoa1900866","journal-title":"N Engl J Med"},{"issue":"22","key":"4612_CR41","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP et al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381(22):2114\u20132124. https:\/\/doi.org\/10.1056\/NEJMoa1901747","journal-title":"N Engl J Med"},{"issue":"5","key":"4612_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/s1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y et al (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19(5):402\u2013412. https:\/\/doi.org\/10.1016\/s1474-4422(20)30078-8","journal-title":"Lancet Neurol"},{"issue":"5","key":"4612_CR43","doi-asserted-by":"publisher","first-page":"Cd011884","DOI":"10.1002\/14651858.CD011884.pub2","volume":"5","author":"MT Samara","year":"2018","unstructured":"Samara MT, Klupp E, Helfer B, Rothe PH, Schneider-Thoma J, Leucht S (2018) Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. Cochrane Database Syst Rev 5(5):Cd011884. https:\/\/doi.org\/10.1002\/14651858.CD011884.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4612_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12967-021-03209-2","volume":"20","author":"WZ Lin","year":"2022","unstructured":"Lin WZ, Liu YC, Lee MC, Tang CT, Wu GJ, Chang YT, Chu CM, Shiau CY (2022) From GWAS to drug screening: repurposing antipsychotics for glioblastoma. J Transl Med 20(1):70. https:\/\/doi.org\/10.1186\/s12967-021-03209-2","journal-title":"J Transl Med"},{"issue":"1","key":"4612_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3168\/jds.2023-23441","volume":"107","author":"MR Rezaei Ahvanooei","year":"2024","unstructured":"Rezaei Ahvanooei MR, Norouzian MA, Piray AH, Vahmani P, Ghaffari MH (2024) Effects of monensin supplementation on rumen fermentation, methane emissions, nitrogen balance, and metabolic responses of dairy cows: a systematic review and dose-response meta-analysis. J Dairy Sci 107(1):607\u2013624. https:\/\/doi.org\/10.3168\/jds.2023-23441","journal-title":"J Dairy Sci"},{"issue":"12","key":"4612_CR46","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","volume":"17","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17(12):1206\u20131227. https:\/\/doi.org\/10.1038\/mp.2012.47","journal-title":"Mol Psychiatry"},{"issue":"9","key":"4612_CR47","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ctrv.2014.07.003","volume":"40","author":"H Oettle","year":"2014","unstructured":"Oettle H (2014) Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev 40(9):1039\u20131047. https:\/\/doi.org\/10.1016\/j.ctrv.2014.07.003","journal-title":"Cancer Treat Rev"},{"key":"4612_CR48","doi-asserted-by":"publisher","first-page":"105295","DOI":"10.1016\/j.phrs.2020.105295","volume":"163","author":"Y Xia","year":"2021","unstructured":"Xia Y, Xu F, Xiong M, Yang H, Lin W, Xie Y, Xi H, Xue Q et al (2021) Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux. Pharmacol Res 163:105295. https:\/\/doi.org\/10.1016\/j.phrs.2020.105295","journal-title":"Pharmacol Res"},{"issue":"1","key":"4612_CR49","first-page":"237","volume":"28","author":"GJ Peters","year":"2006","unstructured":"Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC et al (2006) Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 28(1):237\u2013244","journal-title":"Int J Oncol"},{"key":"4612_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1128\/aac.7.3.349","volume":"7","author":"ME Haney Jr","year":"1967","unstructured":"Haney ME Jr, Hoehn MM (1967) Monensin, a new biologically active compound. I Discovery and isolation. Antimicrob Agents Chemother (Bethesda) 7:349\u2013352. https:\/\/doi.org\/10.1128\/aac.7.3.349","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"issue":"7708","key":"4612_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","volume":"558","author":"BB Sun","year":"2018","unstructured":"Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T et al (2018) Genomic atlas of the human plasma proteome. Nature 558(7708):73\u201379. https:\/\/doi.org\/10.1038\/s41586-018-0175-2","journal-title":"Nature"},{"issue":"5","key":"4612_CR52","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.kint.2022.07.005","volume":"102","author":"A Surapaneni","year":"2022","unstructured":"Surapaneni A, Schlosser P, Zhou L, Liu C, Chatterjee N, Arking DE, Dutta D, Coresh J et al (2022) Identification of 969 protein quantitative trait loci in an African American population with kidney disease attributed to hypertension. Kidney Int 102(5):1167\u20131177. https:\/\/doi.org\/10.1016\/j.kint.2022.07.005","journal-title":"Kidney Int"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04612-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-024-04612-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04612-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T20:08:57Z","timestamp":1743365337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-024-04612-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4612"],"URL":"https:\/\/doi.org\/10.1007\/s12035-024-04612-8","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}